1. Medtech Insight
  2. >>Business
  3. >>R&D
  4. >>Clinical Trials

EuroPCR 2018: Real-World TAVR Data Show Consistent Performance With Edwards, Abbott, And Medtronic's Systems

 
• By Catherine Longworth

New real-world data on Edward Lifesciences real-world data for its transcatheter aortic valve replacement Sapien 3 valve are among the highlights from the early Hot Line/Late-Breaking Trial sessions at the EuroPCR conference in Paris.

MT1805_Eiffel Tower_710380270 _1200
EuroPCR 2018 is held in Paris, France on May 22-25

EuroPCR, the annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), featured a series of presentations of new "real-world" data on transcatheter aortic valve systems during a May 22 Late-Breaking Trial session, including new outcomes with Edwards Lifesciences Corp.'s Sapien 3, Abbott Laboratories Inc.'s Portico, and Medtronic PLC's CoreValve Evolut R.

Edwards' Sapien 3 transcatheter aortic valve is performing as well in the real-world intermediate surgical-risk patients as it did...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

HistoSonics Closed $250M Funding To Expand, But IPO ‘Not Immediate Priority,’ Says CEO

 
• By Marion Webb

The $250m in new funding from HistoSonics’ new owners and new investors Thiel Bio and Founders Fund will expand its histotripsy platform globally, advance new indications, and scale operations. CEO Mike Blue tells Medtech Insight that an IPO isn’t an immediate priority.

Successful Diagnostics Alter Clinical Pathways, Says NHS Foundation Trust Leader

 
• By Natasha Barrow

Evidence-based testing in real clinical settings and diagnostics tailored to community needs are crucial adoption success factors for new IVDs, Michael Wright, joint medical director at Newcastle Hospitals NHS Foundation Trust, told Medtech Insight at a regional UK meeting.

MedTech Innovator Winner Armor Medical Hopes To Reduce 90% Of Preventable Maternal Deaths

 
• By Marion Webb

Armor Medical’s wrist-worn wearable detected postpartum hemorrhage five times earlier than standard care in earlier studies. After surviving near-fatal hemorrhage herself, co-founder/CEO Kelsey Mayo aims to bring the device to market in 2028.

MCEDs ‘Not Ready For Clinic’: Exact Sciences DETECT-A Study Shows ‘Unclear Risk Of Bias’

 
• By Natasha Barrow

Excitement surrounds Multi Cancer Early Detection testing for diagnosing hard-to-detect cancers early and improving patient outcomes. But without full randomized trials – only accuracy studies – physicians lack enough evidence to use them confidently, said physician and researcher Daniel Jonas.

More from R&D

Relief Cardiovascular Brings Relief To Heart Failure Patients With Smart Transcatheter Implant

 
• By Brian Bossetta

Successful implantations of a novel transcatheter mark a major step forward in treating congestion in heart failure, according to the California-based company that developed it. The procedure was part of a feasibility study evaluating the device’s safety.

‘Much-Needed Tool For Large Tissue Biopsy’: Resitu Medical’s Breast Device FDA Authorized

 
• By Natasha Barrow

Resitu Medical has received FDA 510(k) authorization for the RESL09 breast cancer biopsy device. This handheld minimally invasive device excises tissue samples with diameters up to 9 mm and will first reach market in the US. The company plans to expand the tool’s clinical claims and core size range.

Rapid Nexus Bets On Regeneration To Heal Wounds, Stop Amputations, Starting In VA Health Systems

 
• By Marion Webb

Rapid Nexus hopes its regenerative wound-healing system can ease the burden of diabetic foot ulcers and amputations. Backed by early clinical data and $3.8m in seed funding, the start-up is targeting the VA as a launchpad into a $6.5bn US market, with FDA clearance expected later this year.